XTNT (Xtant Medical Holdings) Moat Score: 4/10 (As of Jun. 28, 2026)


XTNT Xtant Medical Holdings Inc XTNT
31 GF Score
Price $0.42
GF Value $0.62
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Xtant Medical Holdings Moat Score?

Xtant Medical Holdings XTNT -0.33% 31 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates XTNT with a GF Score™ of 31/100 and a GF Value™ of $0.62 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Xtant Medical Holdings ranks better than 83.23% on this metric.

Xtant Medical Holdings has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Xtant Medical Holdings has Narrow Moat: Xtant Medical Holdings Inc has a discernible but modest moat due to its niche market presence in medical devices. However, it faces competition and lacks significant pricing power or proprietary technology.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Xtant Medical Holdings might have Narrow Moat - Discernible but modest moat.

Xtant Medical Holdings  (AMEX:XTNT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Xtant Medical Holdings Moat Score Related Terms

XTNT vs MDAI, QTI, POSC: Moat Score Comparison

For the Medical Devices subindustry, Xtant Medical Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xtant Medical Holdings Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Moat Score falls into.


XTNT
31GF Score
Xtant Medical Holdings Inc XTNT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Xtant Medical Holdings (XTNT) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Xtant Medical Holdings ranks #142 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is Xtant Medical Holdings' Moat Score too high?
Xtant Medical Holdings' current Moat Score is 4. Based on the distribution chart, Xtant Medical Holdings ranks #142 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xtant Medical Holdings has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' Moat Score compare to MDAI and QTI?
According to the Medical Devices & Instruments industry distribution chart, Xtant Medical Holdings ranks #142 out of 847 companies for Moat Score. This places Xtant Medical Holdings in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Xtant Medical Holdings's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Possible Value Trap. The stock's GF Value™ is $0.62, compared to a current price of $0.42 — trading 32.2% below its estimated fair value. The current Moat Score is 4. Xtant Medical Holdings' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xtant Medical Holdings (XTNT) Overvalued in 2026?

Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued. The current stock price of $0.42 is trading 32.2% below its estimated GF Value™ of $0.62. GuruFocus considers Xtant Medical Holdings to be Possible Value Trap.

Key valuation signals for XTNT:

  • Moat Score: 4
  • GF Value™: $0.62 vs. price of $0.42 (32.2% below fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xtant Medical Holdings Business Description

Address 664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
31GF Score

Get the complete analysis for XTNT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$0.62
GF Value